Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer
Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Read More
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Read More
Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky, VK Read More
MammaPrint 3-year outcomes with CT with/without anthracycline
ASCO 2024, #511 Presenter: O'Shaughnessy et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreRacial Disparities in HR+HER2- ESBC, Reid et al., SABCS 2023 Abstract
SABCS 2023, PO1-28-01 Authors: Sonya Reid et al.
Read MoreRacial Disparities in Latin American Patients-FLEX, Mazo Canola et al., SABCS 2023 Abstract
SABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreResponse Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreWhole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Read More
ASCO 2020: 8q22 Poster
PUBLICATION: ASCO 20 AUTHORS: Sami Diab, Matei P. Socoteanu, Carlos Read More
